- |||||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Combination therapy, Metastases: Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN (clinicaltrials.gov) - Sep 13, 2023 P2, N=48, Recruiting, Active, not recruiting --> Recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer-A Step before Anakoinosis-Based Personalized Treatment. (Pubmed Central) - Sep 9, 2023 The first molecular target for therapy of HNSCC was EGFR, inhibited by monoclonal antibody cetuximab, but its use in monotherapy is insufficient and induces resistance...The new concept of anakoinosis-based therapy, which means treatment that targets the intercellular and intracellular communication of cancer cells, is thought to be the way to improve the clinical outcome for HNSCC patients. The identification of a link between molecular targeted therapy and anakoinosis raises the potential for further progress in HPV-negative HNSCC therapy.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Real-world evidence, Real-world, Metastases: Real-world study of patients with locally advanced HNSCC in the community oncology setting. (Pubmed Central) - Sep 7, 2023 Covariates associated with poorer survival were age of 60+ years, primary tumor location of hypopharynx or oral cavity and Eastern Cooperative Oncology Group performance status score of 2+. These data describe real-world treatment patterns in locally advanced head and neck squamous cell cancer and sets the baseline to assess outcomes for future studies on the community oncology population.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Oleic acid-induced metastasis of KRAS/p53-mutant colorectal cancer relies on concurrent KRAS activation and IL-8 expression bypassing EGFR activation. (Pubmed Central) - Aug 31, 2023 The hyperlipidemia-triggered metastatic ability of CRC cells under treatments of antioxidants, statin, and cetuximab or knockdown of IL-8, KRAS, and EGFR was evaluated in vitro and in vivo...The high-fat diet mice fed with vitamin E and statin or in IL-8-depleted cells significantly inhibited tumor extravasation and metastatic lung growth of CRC. The antioxidants, statins, and targeting IL-8 may provide better outcomes for treating metastatic CRC that harbors multigene mutations and anti-EGFR resistance.
- |||||||||| MEN1611 / Menarini
Enrollment change, Metastases: MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) (clinicaltrials.gov) - Aug 30, 2023 P1/2, N=29, Active, not recruiting, We further assessed differential molecular pathway activation levels and propose that EGF/human serum-mediated A431 resistance to EGFR drugs can be largely explained by reactivation of the MAPK signaling cascade. N=42 --> 29
- |||||||||| Quality of life in cancer patients undergoing targeted therapies (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2769;
While the selected treatments were generally well-tolerated and resulted in manageable adverse effects, the reported quality of life varied among patients. These findings underscore the importance of considering individual patient factors and tailoring treatment strategies to optimize both clinical outcomes and quality of life in this patient population.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal: Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer. (Pubmed Central) - Aug 29, 2023 Significant improvement in targeted therapy for colorectal cancer (CRC) has occurred over the past few decades since the approval of the EGFR inhibitor cetuximab...Inhibition of PIK3CA MT by PI3K inhibitors restored SMI-4a sensitivity in PIK3CA MT CRC cell lines. Taken together, these results demonstrate that sensitivity to SMI-4a is determined by the PIK3CA genotype and that co-targeting of PI3K and PIM1 in PIK3CA MT CRC patients could be a promising and novel therapeutic approach for refractory CRC patients.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Theranostic Potential of EFNB2 for Cetuximab Resistance in Head and Neck Cancer. (Pubmed Central) - Aug 28, 2023 Taken together, these results demonstrate that sensitivity to SMI-4a is determined by the PIK3CA genotype and that co-targeting of PI3K and PIM1 in PIK3CA MT CRC patients could be a promising and novel therapeutic approach for refractory CRC patients. Thus, EFNB2 has potential to be theranostic marker
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
P2 data, Clinical Trial,Phase II, Journal: NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases. (Pubmed Central) - Aug 26, 2023 Clinically, combination treatments together with cetuximab, an EGFR inhibitor, may overcome acquired oxidative stress resistance in HNC. The use of the triplet regimen in the perioperative period is expected to be safe and effective in patients with resectable BRAF V600E mutant CRM.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab-Conjugated Magnetic Poly(Lactic-co-Glycolic Acid) Nanoparticles for Dual-Targeted Delivery of Irinotecan in Glioma Treatment. (Pubmed Central) - Aug 26, 2023 After loading CPT-11, PLGA@OMNP@CPT-11-CET shows the highest cytotoxicity toward U87 compared with free CPT-11 and PLGA@OMNP@CPT-11 by providing the lowest drug concentration for half-maximal cell death (IC) and the highest rate of cell apoptosis. In orthotopic brain tumor-bearing nude mice with U87 xenografts, intravenous injection of PLGA@OMNP@ CPT-11-CET followed by guidance with a magnetic field provided the best treatment efficacy with the lowest tumor-associated signal intensity from bioluminescence imaging.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Aug 25, 2023 P2, N=128, Active, not recruiting, Trial completion date: Jun 2026 --> Oct 2026 | Trial primary completion date: Jun 2026 --> Oct 2026 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Disease Characteristics, Treatment and Survival for Oropharyngeal Squamous Cell Carcinoma of Elderly (Hall B2; In Person Only) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_2104; We did not note any significant difference in outcomes among elderly patients treated for OP when compared to the younger patients when multi-disciplinary head and neck cancer care is provided. This was noted even though a significantly larger proportion of elderly patients received cetuximab concurrent with RT as opposed to standard of care cisplatin.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Impact of Dosimetric Parameters on Local Control and Toxicity of Head and Neck SBRT (Hall B2; In Person Only) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_2082; We appreciated increased use of immunotherapy in our study population from 2019 onwards. We did not find any relationships between dosimetric parameters and rates of grade 3 or higher toxicity, or local control, though our analysis is limited by a small sample size.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Toxicity and Outcomes of Definitive Local Therapy in Elderly Patients with HPV-Associated Oropharyngeal Cancer (Hall B2; In Person Only) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_2070; Elderly HPV-OPSCC patients treated with definitive intent radiotherapy with or without chemotherapy have favorable disease outcomes with low rates of late toxicity. The Charlson-Comorbidity Index can identify a subset of patients who may have a prolonged OS, and therefore may benefit from more aggressive treatment.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer in NRG/RTOG 1016 (Room 4) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_1831; While this study does not directly refute prior evidence that KRAS- variant patients benefit from radiation + cisplatin and cetuximab, this study does not support the hypothesis that the KRAS- variant is a predictive biomarker of improved outcome in HPV+ oropharyngeal SCC patients treated with IMRT + cetuximab alone, and suggests that for KRAS- variant patients, potential benefits in LRF and acute toxicity with cetuximab may be offset by worse DM and worse late toxicity. Endpoint KRAS -variant Non-variant KRAS and treatment interaction p-value OS 1.10 (0.49, 2.46) 1.10 (0.79, 1.53) 0.99 PFS 1.01 (0.50, 2.04) 1.27 (0.94, 1.73) 0.56 LRF 0.67 (0.25, 1.75) 1.67 (1.09, 2.57) 0.09 DM 3.19 (0.66, 15.34) 1.03 (0.57, 1.86) 0.19 Table 1: Treatment effect HRs and 95% CIs
- |||||||||| cisplatin / Generic mfg.
Effectiveness of Cisplatin in P16+ Oropharyngeal Cancer According to Relative Risk for Cancer Events: Ancillary Analysis of RTOG 1016 (Room 1) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_1404; Relative risk for cancer events should be taken into account when designing deintensification strategies. Abstract 233 - Table 1 PFS OS N Cis Cetux HR (95% CI) p* Cis Cetux HR (95% CI) p* Standard Risk 2-yr (%) 0.94 2-yr (%) Fav 354 92.3 80.9 0.42 (0.25-0.70) 97.1 93.6 0.55 (0.27-1.10) 0.68 Unfav / Low 219 81.0 69.1 0.59 (0.36-0.97) 90.4 82.1 0.72 (0.40-1.28) Unfav / Int 232 79.0 75.3 0.76 (0.47-1.22) 87.7 85.4 0.74 (0.43-1.29) Omega Score 0.046 Low 354 82.7 80.2 0.75 (0.49-1.15) 90.2 89.8 0.90 (0.54-1.50) 0.087 Int 219 86.5 74.2 0.53 (0.30-0.93) 92.3 89.0 0.56 (0.28, 1.14) High 232 88.4 71.7 0.42 (0.25-0.73) 96.4 84.8 0.53 (0.28-1.03) < 0.82** 477 82.6 79.3 0.73 (0.51-1.06) 0.028 90.4 89.4 0.87 (0.56-1.37) 0.052 = 0.82** 328 89.3 71.4 0.41 (0.26-0.66) 95.5 86.3 0.48 (0.28-0.84) *1-tailed interaction **Optimal cutoff (interaction maximized)
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Brachial Plexus Tolerance to Standard Fractionation Re-Irradiation: The Ohio State University Experience (Room 7) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_550; Cisplatin during the 2nd course, cumulative metrics of Dmax 100Gy, mean 70Gy, V80 1.6cc, V90 1cc and V100 0.3cc were associated with development of BPP. Prospective study, longer follow up, and higher numbers are warranted.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, MSi-H Biomarker, Metastases: Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer. (Pubmed Central) - Aug 22, 2023 These findings inform hearing-related outcomes for patients with HPV-associated OPC. Although BRAF, NRAS mutations, and MSI-High status were associated with shorter OS in univariate analyses, only tumour laterality remained an independent prognostic factor in the multivariate analysis.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Metabolomic study: Monitoring Metabolic Changes in Response to Chemotherapies in Cancer with Raman Spectroscopy and Metabolomics. (Pubmed Central) - Aug 22, 2023 Finally, key metabolic pathways enriched were identified when cells are resistant to CTX but downregulated with effective treatment. This study highlights that drug-induced metabolic changes both at the single cell level (Raman) and ensemble level (MS) have the potential to identify mechanisms of response to clinical cancer therapies.
- |||||||||| RX208 / Suzhou NeuPharma, Fosun Pharma
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment (clinicaltrials.gov) - Aug 21, 2023 P2, N=50, Active, not recruiting, Immunotherapy after treatment with ERBITAX showed remarkable promising survival, despite potential selection bias. Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> Jan 2025 | Trial primary completion date: Aug 2022 --> Jun 2024
- |||||||||| barecetamab (ISU104) / ISU Abxis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
P1 data, Clinical Trial,Phase I, Journal, Combination therapy, Monotherapy, Metastases: A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer. (Pubmed Central) - Aug 21, 2023 The recommended phase II dose was determined to be 20?mg/kg triweekly. Barecetamab and in cetuximab combination was well tolerated and demonstrated meaningful antitumor effects.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tagrisso (osimertinib) / AstraZeneca, migoprotafib (RLY-1971) / Relay Therap
Enrollment open, Combination therapy, Metastases: Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 18, 2023 P1, N=172, Recruiting, Together, these findings highlight the potential value of phosphoproteomics to improve our understanding of anti-EGFR treatment and response prediction in mCRC and bring to the forefront alternative drug targets in cetuximab-resistant tumors. Not yet recruiting --> Recruiting
|